Weifeng Xu

Weifeng Xu

Auto-generated profile, based on publicly available information

Weifeng Xu

Merck

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Immunity
Verified
Journal Article
Closed access
BHBing He
Bing He
WXWeifeng Xu
Weifeng Xu
PSPaul A. Santini
Paul A. Santini
APAlexandros D. Polydorides
Alexandros D. Polydorides
ACApril Chiu
April Chiu
ACAndrea Cerutti
Andrea Cerutti

28 January 2007 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
WXWeifeng Xu
Weifeng Xu
BHBing He
Bing He
ACApril Chiu
April Chiu
ACAmy Chadburn
Amy Chadburn
MSMeimei Shan
Meimei Shan
ACAndrea Cerutti
Andrea Cerutti

1 January 2015 in Journal of Immunological Methods
Verified
Journal Article
Closed access
WXWeifeng Xu
Weifeng Xu
HJHao Jiang
Hao Jiang
CTCraig Titsch
Craig Titsch
JHJonathan R. Haulenbeek
Jonathan R. Haulenbeek
RPRenuka C. Pillutla
Renuka C. Pillutla
RDRobert W. Dodge
Robert W. Dodge

1 November 2018 in Journal of Immunological Methods
Verified
Journal Article
Closed access
WXWeifeng Xu
Weifeng Xu
MSMichael Sank
Michael Sank
JCJennifer Cummings
Jennifer Cummings
SCStephen Carl
Stephen Carl
MJMarina Juhel
Marina Juhel
RPRenuka Pillutla
Renuka Pillutla

13 August 2025 in The AAPS Journal
Verified
Journal Article
Open access
MPMichael A. Partridge
Michael A. Partridge
LKLynn Kamen
Lynn Kamen
BWBonnie Wu
Bonnie Wu
HSHelene Solberg
Helene Solberg
JMJim McNally
Jim McNally
JWJoleen White
Joleen White
Neutralizing antibodies (NAbs) to protein therapeutics have traditionally been assumed to be the most impactful subset of anti-drug-antibodies (ADA). NAbs can block the biotherapeutic from engaging its target impacting efficacy and may also cause serious safety events. Stand-alone NAb assays have been employed to detect neutralizing responses, often with reconfigured versions of other assays. These methods have historically been implemented in registrational trials for all molecules, and in early-stage studies for high risk biotherapeutics. However, data has demonstrated that NAb response and ADA magnitude are highly correlated. Additionally, the use of other markers to identify clinically relevant immunogenicity, such as apparent impact on pharmacokinetics (PK) or pharmacodynamics (PD), has been increasing. This manuscript reviews the available data on clinically meaningful immunogenic responses to biologics and proposes a risk-based strategy to determine if and when to employ a stand-alone NAb assay. For molecules with a high risk of safety consequences of immunogenicity (e.g., biological mimics) a NAb assay is recommended. However, for lower-safety risk molecules a stand-alone NAb assay does not enhance the interpretation of clinical data and is likely not needed. A combination of other assessments including ADA status, magnitude and persistence, PK, and PD (and efficacy) can be used as a surrogate for NAb assay data. Integration of data from all clinical evaluations is recommended by Health Authorities and can provide a more accurate overall assessment of neutralizing activity. This approach identifies clinically impactful downstream readouts of neutralizing activity without the need for a stand-alone NAb assay. Graphical Abstract

27 June 2018 in Bioanalysis
Verified
Journal Article
Closed access
WXWeifeng Xu
Weifeng Xu
JCJennifer Cummings
Jennifer Cummings
MSMichael Sank
Michael Sank
MJMarina Juhel
Marina Juhel
XLXuefeng Li
Xuefeng Li
RPRenuka Pillutla
Renuka Pillutla
Ipilimumab is the first US FDA-approved immune checkpoint-blocking antibody drug to harness the patient's own immune cells. One of the postmarketing requirements is to develop a cell-based neutralizing antibody assay. Here, we share some of the most challenging aspects encountered during the assay development: new cell line construction; an unexpected inhibition of T-cell activation by low concentrations of ipilimumab; and two issues caused by sample pretreatment with acid dissociation to overcome drug interference: instability of neutralizing antibody positive control at low pH, and incompatibility of commonly used acid dissociation buffers in the cell assay. After troubleshooting and optimization, we successfully validated the assay and used the assay to test clinical samples to date.